Press Release

PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

New ticker symbol goes into effect immediately

VANCOUVER, BC - January 24, 2024 - PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel derivatives of MDMA (MDXX class molecules), is excited to announce its new OTC ticker, “MDXXF”, which will go into effect on January 24th.

“The new ticker symbol more closely aligns with our business model, the research, development and manufacturing of MDXX class molecules,” said Nick Kadysh, CEO, PharmAla Biotech. “With less than a month to go before FDA is set to announce its assessment approach for MDMA as a therapeutic molecule, and with PharmAla’s globally leading position as an MDMA and MDXX developer, we are more excited than ever for the attention we will be receiving from US audiences in the next few months.”

PharmAla will release its Q1 financial statements on January 29th, 2024.

About PharmAla

PharmAla Biotech Holdings Inc. (CSE: MDMA) is a biotechnology company focused on the research, development, and manufacturing of MDXX class molecules, including MDMA. PharmAla was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials, and to develop novel drugs in the same class. PharmAla is a “regulatory first” organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators. Our team of dedicated professionals includes regulatory experts, scientists, and biomanufacturing professionals. PharmAla has built what it believes to be North America’s first cGMP MDMA value chain, encompassing GMP manufacturing of Active Pharmaceutical Ingredient (API), and drug product formulation. PharmAla’s research and development unit has also begun preclinical research into two patented Novel Chemical Entities (NCEs) based on MDXX class molecules, with proof-of-concept research currently ongoing at the University of Arkansas Medical School.

Media Inquiries

Nicholas Kadysh, CEO